# Australian PI –Afluria® Quad (Influenza Virus Haemagglutinin)

**WARNING: Afluria® Quad vaccine is indicated for use only in persons aged 5 years and over.
It must not be used in persons under 5 years (see Contraindications).**

**For season 2018**

# Name of the medicine

Afluria® Quad vaccine

Inactivated Quadrivalent Influenza Vaccine (split virion)

Suspension for injection

# Qualitative and quantitative composition

This is a purified, inactivated, split virion (split virus) vaccine. Each 0.5 mL dose contains antigens for the 2018 influenza season representative of the following types:
A/Michigan/45/2015 (H1N1) pdm09 – like virus (A/Singapore/GP1908/2015 (IVR-180A)):
 15 micrograms HA\* per dose
A/Singapore/INFIMH-16-0019/2016 (H3N2) – like virus (A/Singapore/INFIMH-16-0019/2016 (IVR-186)):
 15 micrograms HA\* per dose
B/Phuket/3073/2013 - like virus (B/Phuket/3073/2013 (BVR-1B)):
 15 micrograms HA\* per dose
B/Brisbane/60/2008 - like virus (B/Brisbane/46/2015):
 15 micrograms HA\* per dose
\*HA = haemagglutinin

Afluria® Quad is manufactured in eggs and trace amounts of sodium taurodeoxycholate (TDOC), ovalbumin (<1 microgram/0.5mL dose), sucrose, neomycin sulfate, polymyxin B sulfate and propiolactone may be present. For the full list of excipients, see **Section 6.1 - List of excipients**.

The type and amount of viral antigens in Afluria® Quad vaccine conform to the requirements of the Australian Influenza Vaccine Committee for the winter of 2018. The strains chosen for vaccine manufacture are endorsed by the Australian Influenza Vaccine Committee as being antigenically equivalent to the reference virus.

The vaccine is prepared from virus grown in the allantoic cavity of embryonated eggs, purified by zonal centrifugation, inactivated by propiolactone and disrupted by TDOC. Afluria® Quad vaccine conforms in safety and sterility to the requirements of the British Pharmacopoeia.

# Pharmaceutical form

Suspension for injection. Afluria® Quad vaccine is a clear to slightly opaque liquid with some sediment that resuspends upon shaking.

# Clinical particulars

## Therapeutic indications

For the prevention of influenza caused by Influenza Virus, Types A and B contained in the vaccine. The vaccine is indicated for use only in persons aged 5 years and over.

For full details regarding recommendations for influenza vaccination, please refer to the relevant national immunisation guidelines.

## Dose and method of administration

Immunisation should be undertaken in anticipation of seasonal outbreaks of influenza.

### Dose

**Table 1: Afluria® Quad Recommended dosage, by age group**

|  |  |  |
| --- | --- | --- |
| **Age Group** | **Dose** | **Number of Doses** |
| **Paediatrics** |
| 5 to < 9 years | 0.5 mL | 1 or 2a |
| 9 to < 18 years | 0.5 mL | 1 |
| **Adults** |  |  |
| ≥ 18 years | 0.5 mL | 1 |

a Previously unvaccinated children 5 to < 9 years of age should be given 2 doses at least 4 weeks apart

To provide continuing protection, annual vaccination with vaccine containing the most recent strains is necessary.

### Method of administration

Afluria® Quad vaccine should be administered by a health care practitioner in an appropriate setting with an appropriate post-vaccination observation period.

Shake before use. After shaking, the vaccine should appear as a clear to slightly opaque homogenous suspension. The vaccine must be inspected visually prior to administration and should not be used if there is any variation of physical appearance. See **Section 3- Pharmaceutical Form.**

The vaccine should be administered by intramuscular or deep subcutaneous injection.

Afluria® Quad vaccine can be administered concurrently with other vaccines, however separate syringes and a separate arm should be used.

## Contraindications

Afluria® Quad vaccine is contraindicated in children less than 5 years of age because the safety and efficacy in this age group has not been evaluated.

Afluria® Quad vaccine is contraindicated in individuals who have previously experienced:

* Anaphylaxis following a dose of any influenza vaccine
* Anaphylaxis following exposure to any component of the vaccine [**See Section 2 – Qualitative and quantitative composition**]

Refer to **Section 4.4 - Special warnings and precautions for use** below for persons with a known allergy to any component of the vaccine including egg protein.

Immunization should generally be postponed in individuals having a febrile illness or acute infection.

## Special warnings and precautions for use

Afluria® Quad vaccine is not indicated for use in children less than 5 years of age (Refer to Paediatric Use).

As with other injectable vaccines, appropriate medical treatment and supervision should always be available to manage the rare event of an anaphylactic reaction following administration of the vaccine especially for individuals who have a known allergy to egg protein. Adrenaline should always be ready for immediate use whenever any injection is given.

In immunocompromised patients the antibody response may be lower.

If Guillain-Barré syndrome has occurred within 6 weeks of previous influenza vaccination, the decision to give Afluria® Quad vaccine should be based on careful consideration of the potential benefits and risks.

### Use in the elderly

The safety and immunogenicity of Afluria® Quad vaccine was evaluated in adults ≥ 65 years in QIV-01 (See **Section 4.8 Adverse Effects (Undesirable effects)** and **Section 5.1 Pharmacodynamic properties, Clinical trials**). There were 541 enrolled subjects aged 65 to < 75 years and 329 enrolled subjects ≥ 75 years. Antibody responses to Afluria® Quad vaccine were non-inferior to comparator trivalent influenza (TIV-1 and TIV-2) responses in adults ≥ 65 years of age, and lower than in younger adults.

### Paediatric use

Afluria® Quad vaccine is not indicated in children less than 5 years of age.

Administration of the 2010 Southern Hemisphere trivalent influenza vaccine (Fluvax® TIV, manufactured by CSL, now Seqirus Pty Ltd) was associated with increased rates of fever and febrile convulsions, predominantly in children below the age of 5 years as compared to previous years.

Following a comprehensive investigation into the 2010 Southern Hemisphere adverse events, Seqirus has modified the manufacturing conditions. A clinical program has subsequently been conducted with Afluria® Quad in adults, and children aged 6 months to less than 18 years. Fever rates in children were lower than those observed in clinical studies conducted prior to 2010 and no related febrile convulsions were reported.

### Effects on laboratory tests

Interference of Afluria® Quad vaccine with laboratory and/or diagnostic tests has not been studied.

## Interactions with other medicines and other forms of interactions

No interaction studies have been performed on interaction between influenza vaccines in general and other vaccines or medications.

## Fertility, pregnancy and lactation

### Effects on fertility

Afluria® Quad vaccine has not been evaluated for possible effect on fertility.

A reproductive study of female rats vaccinated with Seqirus’ trivalent influenza vaccine (Fluvax® TIV) revealed no impairment of fertility.

### Use in pregnancy: Category B2

The safety and effectiveness of Afluria® Quad vaccine has not been evaluated in pregnant women. For recommendations on vaccination of pregnant women refer to national immunisation guidelines.

A rat reproductive and developmental toxicity study has been conducted with Seqirus’ trivalent influenza vaccine (Fluvax® TIV). This study did not demonstrate any maternal or developmental toxicity. Nonclinical studies have not been conducted with Afluria® Quad vaccine.

### Use in lactation

The safety and effectiveness of Afluria® Quad vaccine has not been evaluated in nursing mothers.

## Effects on ability to drive and use machines

The effects of this medicine on a person’s ability to drive and use machines were not assessed as part of its registration.

## Adverse effects (Undesirable effects)

### Clinical trials

Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a vaccine cannot be directly compared to rates in the clinical studies of another vaccine and may not reflect the rates of events observed in clinical practice.

Two clinical studies with Afluria® Quad vaccine have been completed.

QIV-01 (NCT02214225, see http://clinicaltrials.gov) was a randomised, double-blind, active-controlled trial conducted in the US in 3449 subjects aged ≥ 18 years. Subjects in the safety population received one dose of either Afluria® Quad vaccine (N=1721) or one of two formulations of comparator trivalent influenza vaccine (TIV-1 N=864 or TIV-2 N=864) each containing an influenza type B virus that corresponded to one of the two B viruses in Afluria® Quad vaccine (a type B virus of the Victoria lineage or a type B virus of the Yamagata lineage).

Local (injection-site) adverse reactions and systemic adverse events were solicited for 7 days post-vaccination (Table 2). Unsolicited adverse events were collected for 28 days post-vaccination. Serious adverse events were collected for 180 days post-vaccination. All adverse events are presented regardless of any treatment causality assigned by study investigators.

QIV-02 (NCT02545543, see http://clinicaltrials.gov) was a randomised, observer-blind, comparator-controlled trial that evaluated the immunogenicity and safety of Afluria® Quad vaccine in subjects aged 5 to < 18 years with a 2015-2016 comparator quadrivalent influenza vaccine. Study subjects were scheduled to receive either a single vaccination or two-vaccination regimen as clinically indicated. Local (injection site) adverse reactions and systemic adverse events were solicited for 7 days post vaccination (Table 3). Unsolicited adverse events and cellulitis-like reactions at the injection site were collected for 28 days after the last vaccination; and serious adverse events for six months following last vaccination.

#### Adult data

In adults 18 to < 65 years, the most commonly reported injection-site adverse reaction observed in clinical studies with Afluria® Quad vaccine was pain (≥ 40%). The most common systemic adverse events observed were myalgia and headache (≥ 20%). In adults ≥ 65 years of age, the most commonly reported injection-site adverse reaction observed in clinical studies with Afluria® Quad vaccine was pain (≥ 20%). The most common systemic adverse event observed was myalgia (≥ 10%). A small number of adults ≥ 65 years of age (n=4) experienced severe injection site swelling.

**Table 2: QIV-01: Proportion of Subjects per Age Cohort with Any Solicited Local Adverse Reactions or Systemic Adverse Events within 7 Days after Administration of Afluria® Quad vaccine or Trivalent Influenza vaccine (TIV-1 or TIV-2), Irrespective of Causality (Safety population)**

|  |  |
| --- | --- |
|  | **Percentage (%) a of Subjects in each Age Cohort Reporting an Event** |
| **Subjects 18 to < 65 years** | **Subjects ≥ 65 years** |
| **Afluria® Quad vaccine** **N=854 b** | **TIV-1****N=428 b** | **TIV-2****N=430 b** | **Afluria® Quad vaccine** **N=867 b** | **TIV-1****N=436 b** | **TIV-2****N=434 b** |
| **Any** | **Gr 3** | **Any**  | **Gr 3** | **Any** | **Gr 3** | **Any** | **Gr 3** | **Any** | **Gr 3** | **Any** | **Gr 3** |
| **Local Adverse Reactionsc** |
| Pain | 47.9 | 0.7 | 43.7 | 1.4 | 50.7 | 1.2 | 24.6 | 0.1 | 22. 7 | 0 | 21.0 | 0.2 |
| Swelling/Lump | 3.7 | 0.1 | 2.3 | 0 | 3.5 | 0.2 | 3.2 | 0.5 | 1.8 | 0 | 1.6 | 0 |
| Redness | 2.9 | 0 | 2.8 | 0 | 2.8 | 0 | 4.2 | 0.3 | 2.1 | 0 | 2.5 | 0.2 |
| **Systemic Adverse Eventsd** |
| Myalgia (muscle ache) | 25.5 | 1.9 | 23.4 | 1.4 | 24.2 | 1.2 | 12.7 | 0.3 | 14.0 | 0.7 | 12.2 | 0.5 |
| Headache | 21.7 | 1.7 | 15.2 | 0.9 | 19.1 | 1.2 | 8.4 | 0 | 7. 1 | 0.2 | 7.8 | 0.7 |
| Malaise | 8.9 | 0.7 | 9.1 | 0 | 9.3 | 0.7 | 4.4 | 0.5 | 5.0 | 0.2 | 5.1 | 0.2 |
| Nausea | 6.9 | 0.6 | 7.7 | 0.5 | 6.3 | 1.2 | 1.6 | 0 | 1.8 | 0 | 2.1 | 0.2 |
| Chills | 4.8 | 0.6 | 4.4 | 0.2 | 4.7 | 0.5 | 2.0 | 0 | 2.1 | 0.5 | 1.4 | 0.2 |
| Vomiting | 1.5 | 0.4 | 0.9 | 0 | 2.3 | 0.7 | 0.5 | 0.1 | 0 | 0 | 0.7 | 0.2 |
| Fever | 1.1 | 0.4 | 0.9 | 0 | 0.5 | 0 | 0.2 | 0 | 0.9 | 0 | 0.5 | 0.2 |

Abbreviations: Gr 3, Grade 3.

a Proportion of subjects reporting each solicited local adverse reaction or systemic adverse event by study vaccine group, based on the number of subjects contributing any follow up safety information for at least one data value of an individual sign/symptom.

b N = number of subjects in the Safety Population Subgroup for each study vaccine group.

c Local adverse reactions: Grade 3 pain is that which prevents daily activity; Swelling/Lump and redness: any = ≥ 20 mm diameter, Grade 3 = ≥100 mm diameter

d Systemic adverse events: Fever: any = ≥ 38.0°C, Grade 3 = ≥ 39.0°C, Grade 3 for all other adverse events is that which prevents daily activity.

In adults 18 to < 65 years who received Afluria® Quad vaccine, commonly reported unsolicited adverse events were headache (5.3%), oropharyngeal pain (2.5%), back pain (1.9%), diarrhoea (1.6%), cough (1.3%) and nausea (1.1%). In adults ≥ 65 years who received Afluria® Quad vaccine, commonly reported unsolicited adverse events were headache (2.3%), rhinorrhoea (1.3%), oropharyngeal pain (1.2%) and back pain (1.2%).

#### Paediatric data

Afluria® Quad vaccine was administered to children 5 to < 18 years of age in Study QIV-02.

In children 5 to < 18 years, the most common (≥ 10%) injection site reactions were pain (51.4%), redness (17.1%), and induration/swelling (13.8%); the most common solicited systemic adverse events were headache (15.5%) and myalgia (13.1%).

**Table 3: QIV-02: Proportion of Subjects Per Age Cohort with Any Solicited Local Adverse Reactions or Systemic Adverse Events within 7 Days after Administration of Afluria® Quad Vaccine or Comparator QIV**

|  |  |
| --- | --- |
|  | **Percentage (%) a of Subjects in each Age Cohort Reporting an Event** |
| **Subjects 5 to < 9 years** | **Subjects 9 to < 18 years** |
| **Afluria® Quad vaccine** **N=829 b** | **Comparator QIV****N=274 b** | **Afluria® Quad vaccine** **N=792 b** | **Comparator QIV****N=261 b** |
| **Any** | **Gr 3** | **Any** | **Gr 3** | **Any** | **Gr 3** | **Any** | **Gr 3** |
| **Local Adverse Reactions c** |
| Pain | 51.3 | 0.8 | 49.6 | 0.7 | 51.5 | 0.3 | 45.2 | 0.4 |
| Redness | 19.4 | 3.5 | 18.6 | 1.8 | 14.8 | 1.9 | 16.1 | 1.9 |
| Swelling/Lump | 15.3 | 3.4 | 12.4 | 2.2 | 12.2 | 2.0 | 10.7 | 1.9 |
| **Systemic Adverse Events d** |
| Headache | 12.3 | 0.1 | 10.6 | 0.4 | 18.8 | 0.4 | 14.6 | 0.4 |
| Myalgia | 9.8 | 0.1 | 11.3 | 0.4 | 16.7 | 0.3 | 11.1 | 0.4 |
| Malaise and Fatigue | 8.8 | 0.4 | 5.8 | 0 | 10.0 | 0.4 | 7.7 | 0 |
| Nausea | 7.1 | 0.1 | 8.4 | 0 | 7.7 | 0 | 8.0 | 0 |
| Diarrhoea | 5.2 | 0 | 3.6 | 0 | 5.4 | 0 | 4.2 | 0 |
| Fever | 4.5 | 1.2 | 3.6 | 0.7 | 2.1 | 0.5 | 0.8 | 0 |
| Vomiting | 2.4 | 0.2 | 4.4 | 0 | 1.8 | 0 | 2.3 | 0 |

Abbreviations: Gr 3, Grade 3; Comparator QIV, Fluarix® Quadrivalent [GlaxoSmithKline Biologicals])

a Percent (%) is derived from the number of subjects that reported the event divided by the Solicited Safety Population in each vaccine group and age cohort.

b N = number of subjects in the Solicited Safety Population (subjects who were vaccinated and provided any solicited safety data) for each study vaccine group. Solicited Safety Population was the same for each event.

c Local adverse reactions: Grade 3 pain is that which prevents daily activity; Swelling/Lump and redness: any = > 0mm diameter, Grade 3 = > 30mm diameter.

d Systemic adverse events: Fever: any = ≥ 38.0°C, Grade 3 = ≥ 39.0°C; Grade 3 for all other adverse events is that which prevents daily activity.

There were no vaccine-related deaths reported in this paediatric study QIV-02. There was one vaccine-related serious adverse event (influenza) reported in this study.

One subject experienced a cellulitis-like reaction (defined as concurrent severe pain, redness and swelling) at the injection site after vaccination with Afluria® Quad vaccine.

In children 5 to < 18 years administered Afluria® Quad vaccine, cough (2.1%) was the most commonly reported unsolicited adverse event. Other commonly reported unsolicited adverse events (reported by ≥ 1% of subjects) were oropharyngeal pain (1.3%), pyrexia (1.3%) and upper respiratory tract infection (1.1%).

The most commonly reported unsolicited adverse events among subjects who received Afluria® Quad vaccine in ages 5 to < 9 years following the first or second dose included cough (2.8%), pyrexia (2.1%), headache (1.2%), rhinorrhoea (1.2%), upper respiratory tract infection (1.2%), influenza-like illness (1.0%), and oropharyngeal pain (1.0%).

For subjects aged 9 to < 18 years who received Afluria® Quad vaccine, the most common unsolicited adverse events included oropharyngeal pain (1.6%), cough (1.3%), and upper respiratory tract infection (1.0%).

### Post-marketing surveillance

There are limited post-marketing data available for Afluria® Quad vaccine.

The Afluria® Quad vaccine formulation is based on Seqirus’ trivalent influenza vaccine (Fluvax® TIV), with the exception of an additional B influenza strain.

The adverse events spontaneously reported during post approval use of Fluvax® TIV are presented below.

*Blood and Lymphatic System Disorders*Thrombocytopoenia.

*Immune System Disorders*Allergic or immediate hypersensitivity reactions including anaphylactic shock.

*Nervous System Disorders*Neuralgia, paraesthesia and convulsions (including febrile convulsions), encephalomyelitis, neuritis or neuropathy, and Guillain-Barré syndrome.

*Vascular Disorders*Vasculitis which may be associated with transient renal involvement.

*Skin and Subcutaneous Tissue Disorders*Pruritus, urticaria and rash.

*General Disorders and Administration Site Conditions*Cellulitis and large injection site swelling
Influenza-like illness.

### Reporting suspected adverse reactions

Reporting suspected adverse reactions after registration of the medicinal product is important. It allows continued monitoring of the benefit-risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions at <http://www.tga.gov.au/reporting-problems>

## Overdose

There is no specific information on overdose of Influenza Vaccines.

For information on the management of overdose, contact the Poison Information Centre on 131126 (Australia) or the New Zealand Poisons Centre on 0800 POISON or 0800 764 766 (New Zealand).

# Pharmacological properties

## Pharmacodynamic properties

### Mechanism of action

Afluria® Quad vaccine has been shown to induce antibodies to the viral surface glycoprotein, haemagglutinin. These antibodies are important in the prevention of natural infection.

Specific levels of haemagglutination inhibition (HI) antibody titres post-vaccination with inactivated influenza vaccine have not been correlated with protection from influenza virus. In some human studies, antibody titres of 1:40 or greater have been associated with protection from influenza illness in up to 50% of subjects. Antibodies against one influenza virus type or subtype confers limited or no protection against another. Furthermore, antibody to one antigenic variant of influenza virus might not protect against a new antigenic variant of the same type or subtype.

Annual revaccination with the current vaccine is recommended because immunity declines during the year after vaccination and circulating strains of influenza virus change from year to year.

### Clinical trials

#### Adult studies

One clinical study has been completed with Afluria® Quad vaccine in adults 18 years and older.

QIV-01 (NCT02214225, see http://clinicaltrials.gov) was a randomised, double-blind, active comparator-controlled trial conducted in the US in adults aged 18 years and older. Subjects in the per protocol population that was used for the primary immunogenicity analysis received one dose of either Afluria® Quad vaccine (N=1691) or one of two formulations of comparator trivalent influenza vaccine (TIV-1 N=854 or TIV-2 N=850), each containing an influenza type B virus that corresponded to one of the two B viruses in Afluria® Quad vaccine (a type B virus of the Victoria lineage or a type B virus of the Yamagata lineage). The mean age of the enrolled population was 58 years. 57% were female, 82% were White and 16% Black/African American. The age sub-groups were 18 to < 65 years and ≥ 65 years with a mean age of 43 years and 73 years, respectively. Post-vaccination immunogenicity was evaluated on sera obtained 21 days after administration of a single dose of Afluria® Quad vaccine or TIV.

The co-primary endpoints were HI Geometric Mean Titre (GMT) ratios (adjusted for baseline HI titres) and the difference in seroconversion rates for each vaccine strain, 21 days after the vaccination. Pre-specified non-inferiority criteria required that the upper bound of the 2-sided 95% CI of the GMT ratio (TIV/Afluria® Quad vaccine) did not exceed 1.5 and the upper bound of the 2-sided 95% CI of the seroconversion rate difference (TIV minus Afluria® Quad vaccine) did not exceed 10% for each strain.

Serum HI antibody responses to Afluria® Quad vaccine were non-inferior to both TIVs for all influenza strains. Additionally, non-inferiority was demonstrated for both endpoints in both age sub-groups, adults aged 18 to < 65 years and ≥ 65 years (Table 4), for all strains. Antibody responses were lower in adults aged ≥ 65 years.

Superiority of the immune response to each of the influenza B strains contained in Afluria® Quad vaccine was shown relative to the antibody response after vaccination with TIV formulations not containing that B lineage strain. Superiority against the alternate B strain was also demonstrated for each of the influenza B strains in both age sub-groups; 18 to < 65 years and ≥ 65 years.

Post-hoc analyses of immunogenicity by gender did not demonstrate significant differences between males and females. The study population was not sufficiently diverse to assess differences between races or ethnicities.

Table 4: QIV-01: Post-Vaccination HI Antibody GMTs, Seroconversion Rates, and Analyses of Non-Inferiority of Afluria® Quad vaccine Relative to Trivalent Influenza Vaccine (TIV) for each Strain, at 21 Days Post-Vaccination by Age Cohort (Per Protocol Population)

|  | **Post-vaccination GMT** a | **GMT Ratio** | **Seroconversion %** b | **Difference** | **Met both pre-defined non-inferiority criteria?** c |
| --- | --- | --- | --- | --- | --- |
| **Strain** | **Afluria® Quadvaccine** | **Pooled TIV or TIV-1** **(B Yam)** **or TIV-2** **(B Vic)** | **Pooled TIV or TIV-1****or TIV-2 over****Afluria® Quadvaccine (95% CI)** |  **Afluria® Quad vaccine** | **Pooled TIV or TIV-1** **(B Yam)** **or TIV-2** **(B Vic)** | **Pooled TIV or TIV-1****or TIV-2 minus** **Afluria® Quad vaccine (95% CI)** |
| **18 to < 65 years** | **Afluria® Quad vaccine N=835, Pooled TIV N=845, TIV-1 N=424, TIV-2 N=421** |
| A/H1N1 | 432.7 | 402.8 | 0.93 d (0.85, 1.02) | 51.3 | 49.1 | -2.1 g (-6.9, 2.7) | Yes |
| A/H3N2 | 569.1 | 515.1 | 0.91 d (0.83, 0.99) | 56.3 | 51.7 | -4.6 g (-9.4, 0.2) | Yes |
| B/YAM | 92.3 | 79.3 | 0.86 e (0.76, 0.97) | 45.7 | 41.3 | -4.5 h (-10.3, 1.4) | Yes |
| B/VIC | 110.7 | 95.2 | 0.86 f (0.76, 0.98) | 57.6 | 53.0 | -4.6 i (-10.5, 1.2) | Yes |
| **≥ 65 years** | **Afluria® Quad vaccine N=856, Pooled TIV N=859, TIV-1 N=430, TIV-2 N=429** |
| A/H1N1 | 211.4 | 199.8 | 0.95 d (0.88, 1.02) | 26.6 | 26.4 | -0.2 g (-5.0, 4.5) | Yes |
| A/H3N2 | 419.5 | 400.0 | 0.95 d (0.89, 1.02) | 25.9 | 27.0 | 1.1 g (-3.7, 5.8) | Yes |
| B/YAM | 43.3 | 39.1 | 0.90 e(0.84, 0.97) | 16.6 | 14.4 | -2.2 h (-8.0, 3.6) | Yes |
| B/VIC | 66.1 | 68.4 | 1.03 f (0.94, 1.14) | 23.5 | 24.7 | 1.2 i (-4.6, 7.0) | Yes |

Abbreviations: CI, confidence interval; GMT, geometric mean titre..

a GMT results were modelled on a multi-variable adjusted analysis including gender, vaccination history, pre-vaccination HI titers and other factors.

b Seroconversion rate is defined as a 4-fold increase in post-vaccination HI antibody titre from pre-vaccination titre ≥ 1:10 or an increase in titre from < 1:10 to ≥ 1:40.

c  Non-inferiority (NI) criteria for the GMT ratio: upper bound of 2-sided 95% CI on the ratio of Pooled TIV or TIV-1 (B Yamagata) or TIV-2 (B Victoria)/ Afluria® Quad vaccine. GMT should not exceed 1.5. NI criteria for the seroconversion rate (SCR) difference: upper bound of 2-sided 95% CI on the difference between SCR Pooled TIV or TIV-1 (B Yamagata) or TIV-2 (B Victoria) minus Afluria® Quad vaccine should not exceed 10%.

d  Pooled TIV/Afluria® Quad vaccine

e  TIV-1 (B Yamagata)/ Afluria® Quad vaccine

f  TIV-2 (B Victoria)/Afluria® Quad vaccine

g  Pooled TIV - Afluria® Quad vaccine

h  TIV-1 (B Yamagata) - Afluria® Quad vaccine

i TIV-2 (B Victoria) - Afluria® Quad vaccine

#### Paediatric studies

One clinical study has been completed with Afluria® Quad vaccine in children aged 5 to < 18 years of age.

QIV-02 (NCT02545543, see http://clinicaltrials.gov) was a randomised, observer-blinded, comparator-controlled trial conducted in the US in children 5 to < 18 years of age. Subjects received either one or two doses of either Afluria® Quad vaccine (N=1605) or a comparator quadrivalent influenza vaccine (N=528) in a 3:1 randomisation treatment schedule. Subjects 5 to < 9 years of age were eligible to receive a second dose at least 28 days after the first dose depending on their influenza vaccination history. Approximately 25% of subjects in each treatment group in the 5 to < 9 years of age sub-group received two vaccine doses. Baseline serology prior to vaccination and sera obtained 28 days after the last vaccination dose was collected and immunogenicity was evaluated by HI assay.

The co-primary endpoints were HI Geometric Mean Titres (GMT) (adjusted for baseline HI titres and other covariates) and seroconversion rates for each vaccine strain, 28 days after the last vaccination. Pre-specified non-inferiority criteria required that the upper bound of the 2-sided 95% CI of the GMT ratio (Comparator QIV/Afluria® Quad vaccine) did not exceed 1.5 and the upper bound of the 2-sided 95% CI of the seroconversion rate difference (Comparator QIV minus Afluria® Quad vaccine) did not exceed 10% for each strain.

Serum HI antibody responses to Afluria® Quad vaccine were non-inferior for both GMT and seroconversion rates relative to the Comparator QIV for all influenza strains (Table 5). Analyses of immunogenicity endpoints by gender did not demonstrate meaningful differences between males and females. The study population was not sufficiently diverse to assess differences between races or ethnicities.

Table 5: QIV-02: Post-Vaccination HI Antibody GMTs, Seroconversion Rates, and Analyses of Non-Inferiority of Afluria® Quad Vaccine Relative to Comparator QIV for each Strain 28 Days after Last Vaccination Among a Paediatric Population 5 to < 18 Years of Age (Per Protocol Population)f

|  | **Post-vaccination GMT**  | **GMT****Ratio a** | **Seroconversion % b** | **Difference c** | **Met both pre-defined non-inferiority criteria? d** |
| --- | --- | --- | --- | --- | --- |
| **Strain** | **Afluria**® **Quad vaccineN=1605** | **Comparator QIVN=528** | **Comparator QIV over** **Afluria**®**Quad** **Vaccine(95% CI)** | **Afluria**® **Quad vaccine N=1605****(95% CI)** | **Comparator QIVN=528****(95% CI)** | **Comparator QIV minus** **Afluria** **Quad™** **vaccine (95% CI)** |
| A/H1N1 | 952.6 (n=1604 e) | 958.8  | 1.01 (0.93, 1.09) | 66.4(64.0, 68.7) | 63.3(59.0, 67.4) | -3.1(-8.0, 1.8) | Yes |
| A/H3N2 | 886.4 (n=1604 e) | 930.6 | 1.05 (0.96, 1.15) | 82.9(81.0, 84.7) | 83.3(79.9, 86.4) | 0.4(-4.5, 5.3) | Yes |
| B/YAM | 60.9 (n=1604 e) | 54.3 | 0.89 (0.81, 0.98) | 58.5(56.0, 60.9) | 55.1(50.8, 59.4) | -3.4(-8.3, 1.5)  | Yes |
| B/VIC | 145.0 (n=1604 e) | 133.4 | 0.92(0.83, 1.02) | 72.1(69.8, 74.3) | 70.1(66.0, 74.0) | -2.0(-6.9, 2.9) | Yes |

Abbreviations: B/VIC, B Victoria lineage; B/YAM, B Yamagata lineage; CI, confidence interval; Comparator QIV, Fluarix® Quadrivalent [GlaxoSmithKline Biologicals]; GMT (adjusted), geometric mean titre.

a GMT Ratio = Comparator QIV / Afluria® Quad vaccine. Adjusted analysis model: Log-transformed Post-Vaccination HI Titre = Vaccine + Age Strata [5-8, 9-17] + Gender + Vaccination History [y/n] + Log-transformed Pre-Vaccination HI Titre + Site + Number of Doses (1 vs 2) + Age Strata\*Vaccine. The Age Strata\*Vaccine interaction term was excluded from the model fit for the strains B/Yamagata and B/Victoria as the interaction result was non-significant (p>0.05). Least square means were back transformed.

b Seroconversion rate (SCR) was defined as the percentage of subjects with either a pre-vaccination HI titre < 1:10 and a post-vaccination HI titre ≥ 1:40 or a pre-vaccination HI titre ≥ 1:10 and a 4-fold increase in post-vaccination HI titre.

c Seroconversion rate difference = Comparator QIV SCR percentage minus Afluria® Quad vaccine SCR percentage.

d Non-inferiority (NI) criterion for the GMT ratio: upper bound of two-sided 95% CI on the GMT ratio of Comparator QIV/ Afluria® Quad should not exceed 1.5. NI criterion for the SCR difference: upper bound of two‑sided 95% CI on the difference between SCR Comparator QIV – Afluria® Quad vaccine should not exceed 10%.

e Subject 8400394-0046 was excluded from the Per-Protocol Population for the adjusted GMT analysis for the GMT ratio since the subject did not have information on all covariates (unknown pre-vaccination history).

f The Per-Protocol Population comprised all subjects in the Evaluable Population who did not have any protocol deviations that were medically assessed as potentially impacting on immunogenicity results.

## Pharmacokinetic properties

Not applicable.

## Preclinical safety data

No nonclinical studies have been conducted with Afluria® Quad vaccine. A rat reproductive and developmental toxicity study has been conducted with Fluvax® TIV. This study did not demonstrate any maternal or developmental toxicity.

### Genotoxicity

Afluria® Quad vaccine has not been evaluated for genotoxic potential.

### Carcinogenicity

Afluria® Quad vaccine has not been evaluated for carcinogenic potential.

# Pharmaceutical particulars

## List of excipients

Each 0.5 mL dose contains, nominally: sodium chloride 4.1 mg, dibasic sodium phosphate anhydrous 0.3 mg, monobasic sodium phosphate 0.08 mg, potassium chloride 0.02 mg, monobasic potassium phosphate 0.02 mg and calcium chloride 0.5 micrograms.

## Incompatibilities

Incompatibilities were either not assessed or not identified as part of the registration of this medicine.

## Shelf life

In Australia, information on the shelf life can be found on the public summary of the Australian Register of Therapeutic goods (ARTG). The expiry date can be found on the packaging.

## Special precautions for storage

Afluria® Quad vaccine should be stored, protected from light, at 2°C to 8°C. IT MUST NOT BE FROZEN.

## Nature and contents of container

Afluria® Quad vaccine is supplied in a single-dose 0.5 mL pre-filled type 1 glass syringe in pack sizes of 1 or 10.

## Special precautions for disposal

Afluria® Quad vaccine is presented as a single-use syringe and any remaining contents should be discarded in accordance with local requirements.

## Physicochemical properties

Not applicable

# Medicine schedule (Poisons Standard)

Prescription Only Medicine (S4)

# Sponsor

Seqirus Pty Ltd ABN: 26 160 735 035

63 Poplar Road Parkville

VICTORIA 3052 AUSTRALIA

# Date of first approval

22 July 2016

# Date of revision

7 February 2018

## Summary table of changes

|  |  |
| --- | --- |
| Section Changed | Summary of new information |
| 4.1 | New indication for use in children 5 years and older added. |
| 4.2 | Dosing information added for use in children 5 years and older. |
| 4.3 | Contraindications updated regarding use in persons with egg allergy |
| 4.4 | Precautions updated to reference use in children 5 years and older |
| 4.8 | Adverse effects updated with paediatric trial outcomes |
| 5.1 | Updated mechanism of action statements to align with current practice. Clinical trial section updated with paediatric trial outcomes. |

AFLURIA and FLUVAX are registered trademarks of Seqirus UK Limited or its affiliates